CD55 in Cancer: Complementing Functions in a Non-canonical Manner

Overview

Journal Cancer Lett

Specialty Oncology

Date 2022 Oct 10

PMID 36216147

Authors

Rashmi Bharti

Goutam Dey

Feng Lin

Justin Lathia

Ofer Reizes

Affiliations

Soon will be listed here.

Abstract

CD55, or decay accelerating factor, is a membrane lipid microdomain-associated, GPI-anchored protein implicated in the shielding of cells from complement-mediated attack via accelerating decay of C3 and C5. Loss of CD55 is associated with a number of pathologies due to hyperactivation of the complement system. CD55 is also implicated in cancer progression thought to be driven via its role in cell shielding mechanisms. We now appreciate that CD55 can signal intracellularly to promote malignant transformation, cancer progression, cell survival, angiogenesis, and inhibition of apoptosis. Outside-in signaling via CD55 is mediated by signaling pathways including JNK, JAK/STAT, MAPK/NF-κB, and LCK. Moreover, CD55 is enriched in the cancer stem cell (CSC) niche of multiple tumors including breast, ovarian, cervical, and can be induced by chemotherapeutics and hypoxic environments. CSCs are implicated in tumor recurrence and chemoresistance. Here, we review the unexpected roles of CD55 in cancer including the roles of canonical and noncanonical pathways that CD55 orchestrates. We will highlight opportunities for therapeutic targeting CD55 and gaps in the field that require more in-depth mechanistic insights.

Citing Articles

Immune cells mediate the causal pathway linking circulating complements to cancer: A Mendelian randomization study.

Pan H, Jing C Inflamm Res. 2024; 73(12):2141-2152.

PMID: 39352488 DOI: 10.1007/s00011-024-01955-9.

Receptors and Host Factors for Enterovirus Infection: Implications for Cancer Therapy.

Alekseeva O, Hoa L, Vorobyev P, Kochetkov D, Gumennaya Y, Naberezhnaya E Cancers (Basel). 2024; 16(18).

PMID: 39335111 PMC: 11430599. DOI: 10.3390/cancers16183139.

Injectable Hydrogel-Encapsulating Pickering Emulsion for Overcoming Lenvatinib-Resistant Hepatocellular Carcinoma via Cuproptosis Induction and Stemness Inhibition.

Li X, Tang C, Ye H, Fang C Polymers (Basel). 2024; 16(17).

PMID: 39274051 PMC: 11397159. DOI: 10.3390/polym16172418.

The Dual Faces of Oestrogen: The Impact of Exogenous Oestrogen on the Physiological and Pathophysiological Functions of Tissues and Organs.

Bartkowiak-Wieczorek J, Jaros A, Gajdzinska A, Wojtyla-Buciora P, Szymanski I, Szymaniak J Int J Mol Sci. 2024; 25(15).

PMID: 39125736 PMC: 11311417. DOI: 10.3390/ijms25158167.

Lck Function and Modulation: Immune Cytotoxic Response and Tumor Treatment More Than a Simple Event.

De Sanctis J, Garmendia J, Duchova H, Valentini V, Puskasu A, Kubickova A Cancers (Basel). 2024; 16(15).

PMID: 39123358 PMC: 11311849. DOI: 10.3390/cancers16152630.

References

Geis N, Zell S, Rutz R, Li W, Giese T, Mamidi S . Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro. Curr Cancer Drug Targets. 2010; 10(8):922-31. DOI: 10.2174/156800910793357952. View

Weng Z, Lin J, He J, Gao L, Lin S, Tsang L . Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma. Neuro Oncol. 2021; 24(6):872-885. PMC: 9159429. DOI: 10.1093/neuonc/noab241. View

Hilbig D, Dietrich N, Wandel E, Gonsior S, Sittig D, Hamann J . The Interaction of CD97/ADGRE5 With β-Catenin in Adherens Junctions Is Lost During Colorectal Carcinogenesis. Front Oncol. 2018; 8:182. PMC: 5980956. DOI: 10.3389/fonc.2018.00182. View

Crean-Tate K, Braley C, Dey G, Esakov E, Saygin C, Trestan A . Pretreatment with LCK inhibitors chemosensitizes cisplatin-resistant endometrioid ovarian tumors. J Ovarian Res. 2021; 14(1):55. PMC: 8063392. DOI: 10.1186/s13048-021-00797-x. View

Hill A, DeZern A, Kinoshita T, Brodsky R . Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017; 3:17028. PMC: 7879566. DOI: 10.1038/nrdp.2017.28. View

Nagaraj V, King B, Storm P, Vikman P, Ottosson-Laakso E, Blom A . Complement inhibitor CD55 governs the integrity of membrane rafts in pancreatic beta cells, but plays no role in insulin secretion. Biochem Biophys Res Commun. 2015; 460(3):518-24. DOI: 10.1016/j.bbrc.2015.03.062. View

He Z, Wu H, Jiao Y, Zheng J . Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer. Oncol Lett. 2015; 9(2):793-797. PMC: 4301556. DOI: 10.3892/ol.2014.2751. View

Olcina M, Balanis N, Kim R, Aksoy B, Kodysh J, Thompson M . Mutations in an Innate Immunity Pathway Are Associated with Poor Overall Survival Outcomes and Hypoxic Signaling in Cancer. Cell Rep. 2018; 25(13):3721-3732.e6. PMC: 6405289. DOI: 10.1016/j.celrep.2018.11.093. View

Meng Z, Liu M, Hong H, Du Q, Chen Y . Expression and prognostic value of soluble CD97 and its ligand CD55 in intrahepatic cholangiocarcinoma. Tumour Biol. 2017; 39(3):1010428317694319. DOI: 10.1177/1010428317694319. View

10.

Gorter A, Blok V, Haasnoot W, Ensink N, Daha M, Fleuren G . Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis. Lab Invest. 1996; 74(6):1039-49. View

11.

Eales K, Hollinshead K, Tennant D . Hypoxia and metabolic adaptation of cancer cells. Oncogenesis. 2016; 5:e190. PMC: 4728679. DOI: 10.1038/oncsis.2015.50. View

12.

Shin B, Won H, Adams D, Lee S . CD55 Regulates Bone Mass in Mice by Modulating RANKL-Mediated Rac Signaling and Osteoclast Function. J Bone Miner Res. 2019; 35(1):130-142. DOI: 10.1002/jbmr.3861. View

13.

Cheung N, Walter E, Ratnoff W, Tykocinski M, Medof M . Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest. 1988; 81(4):1122-8. PMC: 329640. DOI: 10.1172/JCI113426. View

14.

Han S, Xu C, Wu X, Li J, Liu Z, Zeng Q . The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma. Int J Colorectal Dis. 2010; 25(6):695-702. DOI: 10.1007/s00384-010-0926-5. View

15.

Dzietczenia J, Wrobel T, Mazur G, Poreba R, Jazwiec B, Kuliczkowski K . Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma. Med Oncol. 2009; 27(3):743-6. DOI: 10.1007/s12032-009-9278-9. View

16.

Li L, Spendlove I, Morgan J, Durrant L . CD55 is over-expressed in the tumour environment. Br J Cancer. 2001; 84(1):80-6. PMC: 2363604. DOI: 10.1054/bjoc.2000.1570. View

17.

Dho S, Kim S, Chung C, Cho E, Lee S, Kim J . Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer. Sci Rep. 2018; 8(1):8960. PMC: 5997699. DOI: 10.1038/s41598-018-27355-8. View

18.

Ozen A, Comrie W, Ardy R, Conde C, Dalgic B, Beser O . CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis. N Engl J Med. 2017; 377(1):52-61. PMC: 6690356. DOI: 10.1056/NEJMoa1615887. View

19.

Reis E, Mastellos D, Ricklin D, Mantovani A, Lambris J . Complement in cancer: untangling an intricate relationship. Nat Rev Immunol. 2017; 18(1):5-18. PMC: 5816344. DOI: 10.1038/nri.2017.97. View

20.

Nahta R, Yu D, Hung M, Hortobagyi G, Esteva F . Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006; 3(5):269-80. DOI: 10.1038/ncponc0509. View